PhRMA Wary of FDA’s Call for Antibacterial Superiority Trials

Washington Drug Letter
PhRMA is pushing back against the centerpiece of the FDA’s draft guidance on antibacterial drug development, saying superiority trials for antibacterials that treat drug-resistant infections are “neither routinely possible nor consistently ethical.”

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00